DB05090ExperimentalSmall molecule
FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic... It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
- Mechanism
- Curator reviewed
FP0011 acts on glutamate receptors and protects nerves.
- Primary indication
- Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and parkinson's disease.Curator reviewed
- Code names
- FP0011
Which companies are running trials of FP0011, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account